In summary, these data support the rationale of pharmacologic inhibition of the Id1/NF-κB/MMP-2 or Id1/PI3K/Akt pathways for ovarian cancer therapy and suggest that inhibition of Id1 or its downstream molecule MMP-2 removes the protection of ovarian cancer EPC from angiogenesis. This evidence concerns the gene ID1 and ovarian carcinoma.